Personalized neoantigen-based cancer immunotherapy. A literature review
Introduction: The progress made in cancer immunotherapy and the clinical response of patients who have undergone this type of therapy have made it the fourth pillar of cancer treatment. Objective: To briefly describe the biological rationale of personalized neoantigen-based cancer immunotherapy, t...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidad Nacional de Colombia
2021-05-01
|
| Series: | Revista de la Facultad de Medicina |
| Subjects: | |
| Online Access: | https://revistas.unal.edu.co/index.php/revfacmed/article/view/81633 |
| _version_ | 1797824703884165120 |
|---|---|
| author | Juan Pablo Ortiz-Aguirre Esteban Alejandro Velandia-Vargas Oscar Mauricio Rodríguez-Bohorquez Diego Amaya-Ramírez David Bernal-Estévez Carlos Alberto Parra-López |
| author_facet | Juan Pablo Ortiz-Aguirre Esteban Alejandro Velandia-Vargas Oscar Mauricio Rodríguez-Bohorquez Diego Amaya-Ramírez David Bernal-Estévez Carlos Alberto Parra-López |
| author_sort | Juan Pablo Ortiz-Aguirre |
| collection | DOAJ |
| description | Introduction: The progress made in cancer immunotherapy and the clinical response of patients who have undergone this type of therapy have made it the fourth pillar of cancer treatment.
Objective: To briefly describe the biological rationale of personalized neoantigen-based cancer immunotherapy, the current perspectives regarding its development, and some of the clinical outcomes achieved with this therapy.
Materials and methods: A literature search was performed in PubMed, Scopus and EBSCO using the following search strategy: type of articles: original experimental studies, clinical trials, and narrative and systematic reviews addressing methods to identify mutations found in tumors and cancer immunotherapy strategies based on neoantigen-based vaccines; study population: humans and animal models; publication period: January 1989 - December 2019; language: English and Spanish; search terms: “Immunotherapy”, “Neoplasms”, “Mutation” and “Cancer Vaccines”.
Results: The initial search started with 1 344 records. Once duplicates were removed (n=176), 780 studies were excluded after reading their abstract and title. The full text of 338 articles was read to confirm which met the inclusion criteria, finally including 73 studies for full analysis. All articles retrieved were published in English and were mainly conducted in the USA (43.83%) and Germany (23.65%). In the case of original studies (n=43), 20 were performed in humans only, 9 in animals only, 2 in both models, and 12 used in silico methodology.
Conclusion: Personalized cancer immunotherapy with tumor neoantigen-based vaccines is strongly emerging as a new alternative to treat cancer. However, to achieve its appropriate implementation, it is necessary to use it in combination with conventional treatments, produce more knowledge that helps clarify cancer immunobiology, and reduce the costs associated with its production.
|
| first_indexed | 2024-03-13T10:43:07Z |
| format | Article |
| id | doaj.art-4fb162dd21c444eea6d0fa4f8a6a0c84 |
| institution | Directory Open Access Journal |
| issn | 0120-0011 2357-3848 |
| language | English |
| last_indexed | 2024-03-13T10:43:07Z |
| publishDate | 2021-05-01 |
| publisher | Universidad Nacional de Colombia |
| record_format | Article |
| series | Revista de la Facultad de Medicina |
| spelling | doaj.art-4fb162dd21c444eea6d0fa4f8a6a0c842023-05-17T22:03:17ZengUniversidad Nacional de ColombiaRevista de la Facultad de Medicina0120-00112357-38482021-05-0169310.15446/revfacmed.v69n3.81633Personalized neoantigen-based cancer immunotherapy. A literature reviewJuan Pablo Ortiz-Aguirre0Esteban Alejandro Velandia-Vargas1Oscar Mauricio Rodríguez-Bohorquez2Diego Amaya-Ramírez3David Bernal-Estévez4Carlos Alberto Parra-López5Universidad Nacional de Colombia - Bogotá Campus - Faculty of Medicine - Department of Microbiology - Immunology and Translational Medicine Research Group - Bogotá D.C. - Colombia.Universidad Nacional de Colombia - Bogotá Campus - Faculty of Medicine - Department of Microbiology - Immunology and Translational Medicine Research Group - Bogotá D.C. - Colombia.Universidad Nacional de Colombia - Bogotá Campus - Faculty of Medicine - Department of Microbiology - Immunology and Translational Medicine Research Group - Bogotá D.C. - Colombia.Universidad Nacional de Colombia - Bogotá Campus - Faculty of Engineering and Faculty of Medicine - Master’s Degree in Biomedical Engineering - Bogotá D.C. - Colombia.Fundación Salud de los Andes - Immunology and Clinical Oncology Research Group - Bogotá D.C. - Colombia.Universidad Nacional de Colombia - Bogotá Campus - Faculty of Medicine - Department of Microbiology - Immunology and Translational Medicine Research Group - Bogotá D.C. - Colombia.Introduction: The progress made in cancer immunotherapy and the clinical response of patients who have undergone this type of therapy have made it the fourth pillar of cancer treatment. Objective: To briefly describe the biological rationale of personalized neoantigen-based cancer immunotherapy, the current perspectives regarding its development, and some of the clinical outcomes achieved with this therapy. Materials and methods: A literature search was performed in PubMed, Scopus and EBSCO using the following search strategy: type of articles: original experimental studies, clinical trials, and narrative and systematic reviews addressing methods to identify mutations found in tumors and cancer immunotherapy strategies based on neoantigen-based vaccines; study population: humans and animal models; publication period: January 1989 - December 2019; language: English and Spanish; search terms: “Immunotherapy”, “Neoplasms”, “Mutation” and “Cancer Vaccines”. Results: The initial search started with 1 344 records. Once duplicates were removed (n=176), 780 studies were excluded after reading their abstract and title. The full text of 338 articles was read to confirm which met the inclusion criteria, finally including 73 studies for full analysis. All articles retrieved were published in English and were mainly conducted in the USA (43.83%) and Germany (23.65%). In the case of original studies (n=43), 20 were performed in humans only, 9 in animals only, 2 in both models, and 12 used in silico methodology. Conclusion: Personalized cancer immunotherapy with tumor neoantigen-based vaccines is strongly emerging as a new alternative to treat cancer. However, to achieve its appropriate implementation, it is necessary to use it in combination with conventional treatments, produce more knowledge that helps clarify cancer immunobiology, and reduce the costs associated with its production. https://revistas.unal.edu.co/index.php/revfacmed/article/view/81633ImmunotherapyNeoplasmsMutationCancer Vaccines |
| spellingShingle | Juan Pablo Ortiz-Aguirre Esteban Alejandro Velandia-Vargas Oscar Mauricio Rodríguez-Bohorquez Diego Amaya-Ramírez David Bernal-Estévez Carlos Alberto Parra-López Personalized neoantigen-based cancer immunotherapy. A literature review Revista de la Facultad de Medicina Immunotherapy Neoplasms Mutation Cancer Vaccines |
| title | Personalized neoantigen-based cancer immunotherapy. A literature review |
| title_full | Personalized neoantigen-based cancer immunotherapy. A literature review |
| title_fullStr | Personalized neoantigen-based cancer immunotherapy. A literature review |
| title_full_unstemmed | Personalized neoantigen-based cancer immunotherapy. A literature review |
| title_short | Personalized neoantigen-based cancer immunotherapy. A literature review |
| title_sort | personalized neoantigen based cancer immunotherapy a literature review |
| topic | Immunotherapy Neoplasms Mutation Cancer Vaccines |
| url | https://revistas.unal.edu.co/index.php/revfacmed/article/view/81633 |
| work_keys_str_mv | AT juanpabloortizaguirre personalizedneoantigenbasedcancerimmunotherapyaliteraturereview AT estebanalejandrovelandiavargas personalizedneoantigenbasedcancerimmunotherapyaliteraturereview AT oscarmauriciorodriguezbohorquez personalizedneoantigenbasedcancerimmunotherapyaliteraturereview AT diegoamayaramirez personalizedneoantigenbasedcancerimmunotherapyaliteraturereview AT davidbernalestevez personalizedneoantigenbasedcancerimmunotherapyaliteraturereview AT carlosalbertoparralopez personalizedneoantigenbasedcancerimmunotherapyaliteraturereview |